

# CMV May Cause Blindness in Men; The CBCD Reviews the Medical Evidence

*The human cytomegalovirus (CMV) may be a cause of acute retinal necrosis (ARN), a rare but devastating condition mostly seen in men. (1)*

ROCHESTER, NEW YORK, UNITED STATES OF AMERICA, August 19, 2015 /EINPresswire.com/ --

“Infected with the cytomegalovirus (CMV)? The CBCD recommends [Gene-Eden-VIR](#) or [Novirin](#).” – Greg Bennett, CBCD

According to research, the CMV can cause blindness in men who have a healthy immune system. (1) Dr. Ian Y. L. Yeung and colleagues wrote in an article for International Ophthalmology Clinics that “acute retinal necrosis (ARN) is a ... devastating condition that usually occurs in immunocompetent individuals. (ARN is an inflammatory condition of the eye that can cause retinal detachment and blindness.)The causative agents are thought to be ... cytomegalovirus (CMV) ... (and) ... male sex was a risk factor for severe vision loss at 6 and 12 months.” (1) Another CMV caused eye condition is also more prevalent in men. “CMV retinitis (CMVR) is a similar viral-mediated infectious uveitides that is more common in men ... 60% to 80% of these CMVR patients are male.” (1) CMV retinitis is characterized by lesions on the eye, and it can also lead to blindness. “Similar to ARN ... a secondary retinal detachment can occur .” (1)

The Center for the Biology of Chronic



Disease (CBCD) recommends that men infected with the latent CMV take Gene-Eden-VIR or Novirin to help their immune system target the latent virus. The formula of these natural, antiviral products was designed to help the immune system target latent viruses.

clinical studies that followed FDA guidelines. The studies showed that the Gene-Eden-VIR and Novirin formula is effective against the herpes family of viruses, including the human cytomegalovirus (CMV). The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with the CMV ... reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR.” (2) The study authors also wrote that, “we observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (2)

Both products can be ordered online on the Novirin and Gene-Eden-VIR websites, here:

<http://www.gene-eden-vir.com>

and

<http://www.novirin.com>

Gene-Eden-VIR and Novirin are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

Note: Novirin has the same formula as Gene-Eden-VIR. However, it contains higher quality and more expensive ingredients.

When CMV causes acute retinal necrosis, “viral particles in the retina ... provoke an intense inflammatory response ... characteristic inflammation of the retinal arterioles occurs, resulting in ... necrosis of dependent, downstream retinal tissue ... approximately 50% of patients will develop retinal detachments in the affected eye after ARN; the majority of retinal detachments occur within 3 months of the onset of ARN.” (3) In other words, the virus invades different parts of the eye, which causes massive inflammation. This inflammation severely damages the eye, killing the tissue. This leads to a detachment of the retina, eventually resulting in blindness.

What treatments are available against the cytomegalovirus?

“Several drugs are approved for the treatment of CMV infections in immunocompromised individuals. These drugs include ganciclovir, its oral prodrug valganciclovir, cidofovir, foscavir and fomivirsen. However, the use of these drugs in immunocompetent individuals is limited by their toxicity, poor oral bioavailability, modest efficacy, and the development of drug resistance.” (2) There are also two natural CMV remedies with a clinically proven formula.

The CBCD reminds the public that Gene-Eden-VIR and Novirin are not a cure for conditions caused by CMV. However, two clinical studies showed that their formula decreases symptoms in infected individuals. Specifically, the formula of Gene-Eden-VIR and Novirin was designed to help the immune system target the latent virus.

The CBCD believes that these facts, combined with the medical evidence presented above, indicate the need to target latent viruses like CMV. “We recommend that infected individuals talk to their doctors about Gene-Eden-VIR or Novirin.” – Greg Bennett, CBCD

All orders of Gene-Eden-VIR and Novirin are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1) Ian Y. L. Yeung, MD; Nicholas A. Popp, BS; Chi-Chao Chan, MD "The Role of Sex in Uveitis and Ocular Inflammation" Int Ophthalmol Clin. 2015;55(3):111-131. medscape.com

(2) Polansky H, Itzkovitz E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Pharmacology & Pharmacy, 2013, 4, 1-8  
<http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.VCfZypSSz90>

(3) Lauren Taney, MD and Vinay A. Shah M.D. "Acute retinal necrosis" Published on December 6, 2014. <http://eyewiki.aao.org/>

Greg Bennett  
CBCD  
585-250-9999  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2015 IPD Group, Inc. All Right Reserved.



